Cassava Sciences Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.55 (market cap $339.46M). The key difference: Roundhill S&P 500 0DTE Covered Call Strategy ETF is far larger — about 8.6× Cassava Sciences Inc's market cap, and Roundhill S&P 500 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| FLNA | XDTE | |
|---|---|---|
Market Cap | $39.40M | $339.46M |
Volume | 759,018 | 214,614 |
Sector | Health | Income / Options Overlay |
52-Week High | $4.64 | $44.76 |
52-Week Low | $0.68 | $36.00 |
Typical Hold Time | 37 Days | 54 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →